This year, NeuroEndocrine Cancer Australia continued to expand our reach and impact thanks
to the incredible support of our community. Click below to read the 2025 Impact Report in full.
NECA was invited to participate and co-author in a multidisciplinary working group to conduct a systematic review and meta-analysis to evaluate the current evidence on
The AUS-NET trial commenced in 2022 and is running through to 2027. Across the five Centres of Excellence—The Queen Elizabeth Hospital, Royal North Shore Hospital,
The 2025 CommNETs Annual Meeting was held in Vancouver on 5–6 December, bringing together neuroendocrine cancer specialists from across Commonwealth countries. CommNETs (Commonwealth Neuroendocrine Tumour
NECA was pleased to attend “Unfiltered: Personal Reflections on HTA and Consumer Engagement” with Jo Watson on Thursday 4 December. The event brought together patient
